Our Sites

Since 1989, our Alsace facility has been at the forefront of sterile multidose innovation, leading the way in the development and manufacture of preservative-free sterile products.

The site specialises in the production of suspensions and emulsions, utilising terminal sterilisation to ensure patient safety and product quality.

We’re passionate about pushing the boundaries of what’s possible in sterile manufacturing to deliver safer and more effective therapies.

Since 1992, the Orléans site has served as a specialist development centre, driving innovation in drug formulation and clinical batch production.

Leveraging proven expertise in galenic and analytic development, the site excels in crafting sterile and non-sterile finished dosage forms for Phase 1 to 3 clinical trials, including tablets, capsules, coated pellets, granules and powders.

The team at Orléans doesn’t just stop at clinical batches; they also expertly design products for a seamless transition to commercial manufacturing.

Since 1984, our Provence facility has been a trusted partner for the development and production of freeze-dried drug products.

Committed to delivering the highest standards of quality and reliability, the site ensures your lyophilised products meet the most stringent requirements, offering advanced technology and a GMP- and FDA-certified environment.

Our expert team provides flexible solutions, including dry powder filling, terminal sterilisation and bulk lyophilisation, and is dedicated to collaborating with you to achieve your unique product goals.

Established in 1979, our Erstein facility boasts a long history of expertise in the production of tablets and capsules.

Offering flexible solutions for both generic and brand-name pharmaceuticals, our Erstein site is equipped with advanced technology for the efficient production of your oral solid dose products.

We offer a range of services for tablets, capsules, coated pellets, granules and powders, all supported by a dedicated team and robust quality control processes.

Since 1970, our Dreux facility has been a trusted partner for developing and manufacturing high-quality dry-form products, specialising in sachets and sugar-coated tablets

The site offers comprehensive solutions for tablets, sachets, coated pellets, granules and powders.

Our team at Dreux is committed to delivering the highest standards of quality and efficiency for your large-scale dry-form production needs.

At our Alcalá facility, we collaborate closely with you to deliver high-quality drug products across a range of solid dosage forms, from tablets and capsules to coated pellets, granules and powders. We also offer sterile liquid capabilities, including sterile injectables (liquid and lyophilised vials).

Located near Barcelona, our Parets facility offers multi-functional manufacturing capabilities within an expansive 11,900 m² footprint.

The site has expertise in developing and manufacturing non-sterile drug products and provides advanced solutions for specialised packaging, ensuring we can meet your unique needs.

Our Parets site provides comprehensive services for a wide range of dosage forms, including solids, semi-solids and non-sterile liquids.

Our Pessac facility, strategically located in the second-largest suburb of Bordeaux, specialises in formulation process development and the development and manufacture of controlled-release drugs, coated microgranules and mini-tablets.

With a dedicated team and a commitment to Quality-by-Design principles, the site ensures the highest quality standards throughout your drug product lifecycle.

We leverage our expertise and state-of-the-art 9,700 m² facility to provide tailored solutions that meet your unique needs.

Located near Stockholm, our Uppsala site offers expertise in chemical synthesis, analytical development, bioanalysis and pre-formulation, all within a state-of-the-art facility.

Within our purpose-built 1,300 m² site, our team of scientific experts offers integrated services, including preclinical R&D synthesis, API process development (non-cGMP), preclinical analytical services and pre-formulation studies.

Our preclinical drug substance development expertise ensures a smooth and efficient transition from discovery to development, setting the stage for successful clinical trials.

Our Solna site is dedicated to providing efficient and compliant solutions tailored to the demanding requirements of clinical drug development.

Strategically located near Stockholm, Solna offers specialised expertise in formulation and process development, clinical trial manufacturing and small-scale commercial production, all within a state-of-the-art 3,000 m² facility.

With a team of experts backed by cGMP and EMA certifications, we ensure the highest quality standards throughout your drug product’s lifecycle from Solna.

Located near Stockholm, our 8,000 m2 facility in Strängnäs offers expertise in a range of dosage forms, including tablets, capsules, sachets, and granules for suspension and solution.

Our dedicated team in Strängnäs is ready to collaborate with you on even the most complex projects, including the development and manufacture of beta-lactam products.

Offering comprehensive services, the site supports primary and secondary packaging, serialisation and aggregation, all within a state-of-the-art facility designed for quality and efficiency.

Our Höganäs facility is dedicated to solid-dose manufacturing and specialises in the filling of sachets and stick packs, primarily for powders and granules.

Equipped with state-of-the-art technology for the efficient production and packaging of oral solid dose products, the site’s 4,100 m²  footprint provides efficient and reliable solutions to meet your specific needs.

We offer a range of services, including primary and secondary packaging, serialisation and aggregation, all supported by a team of experts.

Our dedicated commercial-scale manufacturing facility in Karlskoga offers a collaborative environment and expert guidance to support your semi-solid and liquid product needs.

Leveraging a dedicated team and a 5,700 m²  footprint, the Karlskoga site provides comprehensive services, including terminal sterilisation and WFI production.

The site also offers a specialised infrastructure designed to meet the stringent requirements of controlled drug, ophthalmic solution and sterile semi-solid production.